Tumor Immunophenotyping‐Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer

The effectiveness of neoadjuvant immune checkpoint inhibitor (ICI) therapy is confirmed in clinical trials; however, the patients suitable for receiving this therapy remain unspecified. Previous studies have demonstrated that the tumor microenvironment (TME) dominates immunotherapy; therefore, an ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jia‐Bin, Qiu, Qing‐Zhu, Zheng, Qiao‐Ling, Zhao, Ya‐Jun, Xu, Yu, Zhang, Tao, Wang, Shuan‐Hu, Wang, Quan, Jin, Qin‐Wen, Ye, Yin‐Hua, Li, Ping, Xie, Jian‐Wei, Lin, Jian‐Xian, Lu, Jun, Chen, Qi‐Yue, Cao, Long‐Long, Yang, Ying‐Hong, Zheng, Chao‐Hui, Huang, Chang‐Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214263/
https://www.ncbi.nlm.nih.gov/pubmed/36998102
http://dx.doi.org/10.1002/advs.202207417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214263/
https://www.ncbi.nlm.nih.gov/pubmed/36998102
http://dx.doi.org/10.1002/advs.202207417

Ejemplares similares